Inactive Instrument

ATHENEXPAR

Equities

ATNX

US04685N2027

Athenex, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022

March 20, 2023 at 08:11 am

Athenex, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported revenue was USD 25.06 million compared to USD 17.92 million a year ago. Net loss was USD 34.18 million compared to USD 104.39 million a year ago. Basic loss per share from continuing operations was USD 4.28 compared to USD 19.08 a year ago. Diluted loss per share from continuing operations was USD 4.28 compared to USD 19.08 a year ago.

For the full year, the company reported revenue was USD 102.821 million compared to USD 95.369 million a year ago. Net loss was USD 103.427 million compared to USD 199.768 million a year ago. Basic loss per share from continuing operations was USD 15.81 compared to USD 38.44 a year ago. Diluted loss per share from continuing operations was USD 15.81 compared to USD 38.44 a year ago.

Latest news about ATHENEXPAR

Athenex, Inc. Went Out of Business	23-09-22	CI
First Motion for Exclusivity Period Extension Approved For Athenex, Inc.	23-09-18	CI
Liquidation Plan Approved for Athenex, Inc.	23-09-12	CI
First Motion for Exclusivity Period Extension Filed by Athenex, Inc.	23-09-08	CI
Athenex, Inc. Announces the Separation of Joe Annoni as Chief Financial Officer	23-08-17	CI
Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer	23-08-17	CI
Illumina cuts annual profit forecast as biotech funding woes linger	23-08-09	RE
Illumina cuts annual profit forecast	23-08-09	RE
Modified Disclosure Statement Approved on Interim Basis for Athenex, Inc.	23-08-01	CI
Motion for Asset Sale Approved for Athenex, Inc.	23-08-01	CI
Combined Liquidation Plan and Disclosure Statement Filed by Athenex, Inc.	23-07-26	CI
North American Morning Briefing : Beijing Boost Supports Mood; CPI Still The Main Event	23-07-11	DJ
North American Morning Briefing : Stock Futures -2-	23-06-27	DJ
Motion for Asset Sale Approved for Athenex, Inc.	23-06-27	CI
Motion for Asset Sale Approved for Athenex, Inc.	23-06-27	CI
Notice of Selection of Sucessful Bidder Filed by Athenex, Inc.	23-06-22	CI
Motion for Asset Sale Approved for Athenex, Inc.	23-06-21	CI
North American Morning Briefing : Stock Futures -2-	23-06-20	DJ
Notice of Selection of Winning Bidder Filed by Athenex, Inc.	23-06-20	CI
North American Morning Briefing : Investors Brace -2-	23-06-13	DJ
Notice of Extended Bid Deadline Filed by Athenex, Inc.	23-06-07	CI
Stalking Bid Agreement Approved for Athenex, Inc.	23-06-07	CI
North American Morning Briefing : Stocks Poised -2-	23-05-30	DJ
Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index	23-05-24	CI
North American Morning Briefing : Stock Futures -2-	23-05-23	DJ

Chart ATHENEXPAR

Duration

Period

More charts

Company Profile

Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.

Sector

More about the company